Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Korro Bio (KRRO) EBITDA (2019 - 2025)

Korro Bio (KRRO) has disclosed EBITDA for 6 consecutive years, with -$18.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 11.85% year-over-year to -$18.0 million, compared with a TTM value of -$88.8 million through Sep 2025, down 1.76%, and an annual FY2024 reading of -$83.3 million, down 2.64% over the prior year.
  • EBITDA was -$18.0 million for Q3 2025 at Korro Bio, up from -$25.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $5.8 million in Q4 2022 and bottomed at -$25.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$19.8 million, with a median of -$20.4 million recorded in 2024.
  • The sharpest move saw EBITDA soared 127.19% in 2022, then crashed 537.86% in 2023.
  • Year by year, EBITDA stood at -$21.4 million in 2021, then skyrocketed by 127.19% to $5.8 million in 2022, then plummeted by 537.86% to -$25.4 million in 2023, then increased by 15.44% to -$21.5 million in 2024, then grew by 16.19% to -$18.0 million in 2025.
  • Business Quant data shows EBITDA for KRRO at -$18.0 million in Q3 2025, -$25.9 million in Q2 2025, and -$23.4 million in Q1 2025.